May 25, 2017 10:56 AM EDT

New cardio target ANGPTL3 with promising new studies; Liverpool says Redx is delinquent; Aslan's $33M Taipei IPO

→ Regeneron and Ionis each have publications in The New England Journal of Medicine aimed at a brand new cardio target ANGPTL3.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

New car­dio tar­get ANGPTL3 with promis­ing new stud­ies; Liv­er­pool says Redx is delin­quent; Aslan's $33M Taipei IPO